Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Migraines and cluster headaches
Anaphylactic shock
Acute adrenal crisis
Epileptic seizure
Opioid overdose
Rheumatoid arthritis
Temporary paralysis in Parkinson's disease
Severe asthma crisis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Available position and applications
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
First-half 2020 results and business update
First-half 2020 results and business update
Image
Date de parution
2020/09/21
PDF du document
CP_2020_09_Crossject _Resultats semestriels 2020 vdef_ENG .pdf
199.15 KB
